Shares of Bristol-Myers Squibb Co (NYSE:BMY) have earned a consensus rating of “Hold” from the twenty-three analysts that are currently covering the firm, Marketbeat Ratings reports. Three research analysts have rated the stock with a sell recommendation, twelve have assigned a hold recommendation and seven have issued a buy recommendation on the company. The average 1-year target price among brokers that have issued ratings on the stock in the last year is $61.73.
BMY has been the subject of a number of recent analyst reports. JPMorgan Chase & Co. upped their price objective on Bristol-Myers Squibb from $70.00 to $74.00 and gave the company an “overweight” rating in a report on Monday, October 8th. BMO Capital Markets upped their price objective on Bristol-Myers Squibb from $55.00 to $58.00 and gave the company a “market perform” rating in a report on Friday, November 16th. Societe Generale set a $47.00 price objective on Bristol-Myers Squibb and gave the company a “sell” rating in a report on Wednesday, November 14th. William Blair reiterated an “outperform” rating on shares of Bristol-Myers Squibb in a report on Monday, October 22nd. Finally, Citigroup downgraded Bristol-Myers Squibb from a “buy” rating to a “neutral” rating and dropped their price objective for the company from $62.00 to $57.00 in a report on Monday, October 22nd.
Institutional investors have recently made changes to their positions in the business. CSat Investment Advisory L.P. acquired a new position in shares of Bristol-Myers Squibb during the second quarter worth about $113,000. Cypress Capital Management LLC WY boosted its position in Bristol-Myers Squibb by 154.7% during the third quarter. Cypress Capital Management LLC WY now owns 1,910 shares of the biopharmaceutical company’s stock valued at $119,000 after purchasing an additional 1,160 shares during the last quarter. Landaas & Co. WI ADV acquired a new position in Bristol-Myers Squibb during the second quarter valued at approximately $131,000. CLS Investments LLC boosted its position in Bristol-Myers Squibb by 194.3% during the third quarter. CLS Investments LLC now owns 2,575 shares of the biopharmaceutical company’s stock valued at $160,000 after purchasing an additional 1,700 shares during the last quarter. Finally, Selective Wealth Management acquired a new position in Bristol-Myers Squibb during the third quarter valued at approximately $184,000. Institutional investors own 72.74% of the company’s stock.
Bristol-Myers Squibb (NYSE:BMY) last issued its quarterly earnings results on Thursday, October 25th. The biopharmaceutical company reported $1.09 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.91 by $0.18. Bristol-Myers Squibb had a return on equity of 47.89% and a net margin of 6.50%. The business had revenue of $5.69 billion for the quarter, compared to analyst estimates of $5.72 billion. Analysts anticipate that Bristol-Myers Squibb will post 3.87 EPS for the current year.
Bristol-Myers Squibb Company Profile
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, and distributes biopharmaceutical products worldwide. The company offers drugs in various therapeutic classes, such as oncology; cardiovascular; immunoscience; and virology, including human immunodeficiency virus (HIV) infection.
See Also: Rule of 72
Receive News & Ratings for Bristol-Myers Squibb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb and related companies with MarketBeat.com's FREE daily email newsletter.